Rafael Holdings, INC

Rafael Holdings, Inc. provided an investor presentation detailing the progress of its Trappsol Cyclo Phase 3 clinical trial for Niemann-Pick Disease Type C1, with NDA submission anticipated in the second half of 2026.

Rafael Holdings announced third quarter fiscal year 2026 financial results, highlighting the completion of the last patient last visit for its pivotal Phase 3 TransportNPC trial and an expected NDA submission in the second half of calendar 2026.

Rafael Holdings announced the completion of the last patient visit in its pivotal Phase 3 TransportNPC study for Trappsol Cyclo, with topline data expected in late 2026.

Rafael Holdings' subsidiary, Cyclo Therapeutics, has secured an exclusive license from MIT for a patent covering cyclodextrins in Alzheimer's patients with the ApoE4 genetic mutation.

Rafael Holdings announced its second quarter fiscal year 2026 financial results and positive progress in its pivotal Phase 3 TransportNPC study for Niemann-Pick Disease Type C1.

Rafael Holdings, Inc. announced the results of its Annual Meeting, including the election of directors, ratification of its auditor, and approval of an amended equity incentive plan.

Rafael Holdings reports a wider net loss for the nine months ended April 30, 2026, driven by increased R&D spending, while cash reserves decrease.

Rafael Holdings reported a wider net loss for the second fiscal quarter and first half of 2026, driven by significantly increased research and development expenses primarily from its Cyclo acquisition, despite a gain from debt settlement.

Rafael Holdings, Inc. reported a wider net loss in its first fiscal quarter, driven by significantly increased research and development expenses following the acquisition of Cyclo Therapeutics and its pivotal Phase 3 clinical trial for Trappsol Cyclo.

Rafael Holdings, Inc. reported a reduced net loss for the nine months ended April 30, 2025, and significantly boosted its cash reserves by $35.3 million through a recent capital raise, as it consolidates its focus on the lead clinical program, Trappsol Cyclo, following the Cyclo merger.

Rafael Holdings' Q2 2025 results reveal a net loss, influenced by a goodwill impairment in the Infusion Technology segment and fluctuations in the fair value of its investment in Cyclo Therapeutics.

Rafael Holdings reported a net loss of $9 million for the quarter ended October 31, 2024, as it focuses on a planned merger with Cyclo Therapeutics and evaluates its existing assets.

Rafael Holdings reported a reduced net loss for fiscal year 2025, driven by the Cyclo merger and R&D efforts, while advancing its lead drug candidate Trappsol Cyclo for NPC1.

Rafael Holdings has filed an amendment to its annual report to revise a risk factor and include new certifications from its Principal Executive Officer and Principal Financial Officer.

Rafael Holdings files an amended annual report, outlining a strategic shift towards therapeutics and detailing a planned merger with Cyclo Therapeutics.

Rafael Holdings' annual report details a strategic shift towards clinical-stage pharmaceutical investments, particularly focusing on the planned merger with Cyclo Therapeutics and its lead drug, Trappsol Cyclo.

Howard S Jonas, Exec Chairman, CEO & President, a Director and 10% owner of Rafael Holdings, Inc., received 54,945 shares of common stock on July 29, 2026.

Rafael Holdings Inc. executive Howard S. Jonas reported transactions involving Class B Common Stock, including shares withheld for taxes and grants of restricted stock.

Rafael Holdings' Chief Financial Officer, David Polinsky, reported a disposition of 2,318 shares of Class B Common Stock for tax withholding purposes.

Howard S. Jonas, Executive Chairman, CEO & President of Rafael Holdings, reported the sale of 9,826 Class B Common Stock shares to cover tax obligations related to restricted stock vesting.

Rafael Holdings, Inc. Director Markus Sieger acquired 29,528 shares of Class B Common Stock through a restricted stock grant, increasing his beneficial ownership.

Rafael Holdings Director Michael J. Weiss acquired 39,370 shares of Class B Common Stock, increasing his beneficial ownership to 141,861 shares.

Rafael Holdings, Inc. announces its 2026 Annual Meeting of Stockholders to elect directors, ratify auditors, and approve an increase in its equity incentive plan shares.

Rafael Holdings has announced its annual meeting of stockholders to be held on January 9, 2025, where shareholders will vote on the election of directors, the ratification of the company's accounting firm, and an amendment to the equity incentive plan.

Howard Jonas, a significant beneficial owner, has increased his stake in Rafael Holdings, Inc. to 29.2% of outstanding shares and 50.9% of combined voting power following a business combination with Cyclo Therapeutics and participation in a $25.0 million rights offering.

I9 Plus, LLC, a significant shareholder in Rafael Holdings, Inc., has updated its beneficial ownership, reporting recent share sales under a 10b5-1 plan and a substantial purchase through a rights offering.